Durvalumab + Olaparib + Tremelimumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRCA1 Gene Mutation
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Trial Timeline
Jun 29, 2017 → Aug 15, 2024
NCT ID
NCT02953457About Durvalumab + Olaparib + Tremelimumab
Durvalumab + Olaparib + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for BRCA1 Gene Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT02953457. Target conditions include BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma.
What happened to similar drugs?
0 of 1 similar drugs in BRCA1 Gene Mutation were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02953457 | Phase 2 | Completed |
Competing Products
3 competing products in BRCA1 Gene Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olaparib + Olaparib + Placebo + Placebo | AstraZeneca | Phase 3 | 40 |
| Talazoparib Oral Capsule | Pfizer | Phase 1 | 21 |
| INO-5401 + INO-9012 | Inovio Pharmaceuticals | Phase 1 | 23 |